Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

SONN
Sonnet BioTherapeutics Holdings Inc
stock NASDAQ

At Close
5/30/2023 3:59:30 PM EDT
0.4959USD+15.355%(+0.0660)400
0.3680Bid   0.5545Ask   0.1865Spread IEX
Pre-market
5/30/2023 9:29:30 AM EDT
0.4699USD+9.307%(+0.0400)3,410
After-hours
5/30/2023 4:58:30 PM EDT
0.5038USD+1.593%(+0.0079)0
OverviewHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
13.627M
Headquarters
Princeton, New Jersey, USA
Industry
Biotechnology
Next Earnings
2023-08-14 (75d)
Last Split
2022-09-191for14reverse
SONN Stats
Avg. Vol. 10 Day
3,416,107
Avg. Vol. 30 Day
2,220,920
Employees
12
Market Cap
13,626,680
Shares Out.
27,478,686
Float
21,408,095
On/Off Exchange
42%/58%
6 Month Beta
0.46
1 Year Beta
0.30
2 Year Beta
0.80
3 Year Beta
0.77
52 Week Low
0.21
52 Week High
4.56
SMA50
0.28
SMA200
0.80
1 Week
+75.11%
1 Month
+114.40%
3 Month
-40.96%
6 Month
-52.77%
1 Year
-86.52%
2 Year
-97.69%
5 Year
-99.44%
Dec 20, 2021
08:34AM EST  Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $2.5   Benzinga
Dec 17, 2021
07:54AM EST  The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx   Benzinga
06:32AM EST  Sonnet BioTherapeutics Files 10-K   Benzinga
Dec 16, 2021
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021   Benzinga
08:20AM EST  HC Wainwright & Co. Initiates Coverage On Sonnet BioTherapeutics with Buy Rating, Announces Price Target of $2   Benzinga
More News
Profile
Founded in 2011, Sonnet Biotherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and 'hitch-hikes' on human serum albumin (HSA) for transport to target tissues. FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

SONN Stock Summary

Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) stock price today is $0.4959, and today's volume is 400. SONN is up 15.355% today. The 30 day average volume is 2,220,920. SONN market cap is 13.627M with 27,478,686 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC